We are live on ! Find out more
MB

MPM BioImpact Portfolio holdings

AUM $1.64B
1-Year Est. Return 245.64%
This Fund
S&P 500
This Quarter Est. Return
+3.74%
1 Year Est. Return
+245.64%
3 Year Est. Return
+550.3%
5 Year Est. Return
+647.56%
10 Year Est. Return
–
AUM
$644M
AUM Growth
+$21.5M
Cap. Flow
+$87.7M
Cap. Flow %
13.63%
Top 10 Hldgs %
53.54%
Holding
47
New
9
Increased
25
Reduced
4
Closed
3

Top Buys

Rank Stock Value
1
ALKS icon
Alkermes
ALKS
+$13.7M
2
MIRM icon
Mirum Pharmaceuticals
MIRM
+$12.9M
3
SRRK icon
Scholar Rock
SRRK
+$12.6M
4
GH icon
Guardant Health
GH
+$11.6M
5
ALXO icon
ALX Oncology
ALXO
+$11.2M

Top Sells

Rank Stock Value
1
GERN icon
Geron
GERN
+$34.6M
2
VRDN icon
Viridian Therapeutics
VRDN
+$10.8M
3
FOLD
Amicus Therapeutics
FOLD
+$8.47M
4
STRO icon
Sutro Biopharma
STRO
+$4.16M
5
VKTX icon
Viking Therapeutics
VKTX
+$2.03M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AKRO
26
DELISTED
Akero Therapeutics
AKRO
$9.06M 1.41%
385,990
+53,066
+16% +$1.13M
ETNB
27
DELISTED
89bio
ETNB
$8.99M 1.4%
1,121,736
+153,994
+16% +$1.38M
FULC icon
28
Fulcrum Therapeutics
FULC
$294M
$8.96M 1.39%
1,444,851
+307,743
+27% +$2.33M
STRO icon
29
Sutro Biopharma
STRO
$339M
$8.92M 1.39%
304,335
-105,327
-26% -$4.16M
SRRK icon
30
Scholar Rock
SRRK
$7.04B
$8.57M 1.33%
+1,028,330
New +$12.6M
RLAY icon
31
Relay Therapeutics
RLAY
$4.11B
$8.31M 1.29%
1,274,459
+442,442
+53% +$3.02M
RNAC icon
32
Cartesian Therapeutics
RNAC
$290M
$7.01M 1.09%
+259,696
New +$6.2M
RGNX icon
33
Regenxbio
RGNX
$638M
$6.52M 1.01%
557,076
+7,998
+1% +$124K
VKTX icon
34
Viking Therapeutics
VKTX
$3.75B
$6.31M 0.98%
118,960
-31,040
-21% -$2.03M
ZNTL icon
35
Zentalis Pharmaceuticals
ZNTL
$360M
$5.93M 0.92%
1,450,000
-66,183
-4% -$739K
HOWL icon
36
Werewolf Therapeutics
HOWL
$45.8M
$5.83M 0.91%
2,388,011
– –
RPTX
37
DELISTED
Repare Therapeutics
RPTX
$5.41M 0.84%
1,639,849
– –
RNAM
38
DELISTED
Avidity Biosciences
RNAM
$5.11M 0.79%
+125,000
New +$3.59M
CMPX icon
39
Compass Therapeutics
CMPX
$432M
$5.01M 0.78%
5,005,086
+3,033,684
+154% +$4.43M
ADAP
40
DELISTED
Adaptimmune Therapeutics
ADAP
$4.97M 0.77%
5,095,912
– –
IMTX icon
41
Immatics
IMTX
$1.44B
$4.85M 0.75%
417,810
+22,573
+6% +$254K
TRVI icon
42
Trevi Therapeutics
TRVI
$2.39B
$4.5M 0.7%
1,510,174
+169,214
+13% +$470K
VERV
43
DELISTED
Verve Therapeutics
VERV
$3.11M 0.48%
638,163
– –
ALLK
44
DELISTED
Allakos
ALLK
$345K 0.05%
+344,900
New +$410K
FOLD
45
DELISTED
Amicus Therapeutics
FOLD
– –
-718,970
Closed -$8.47M
GERN icon
46
Geron
GERN
$970M
– –
-10,475,675
Closed -$34.6M
VRDN icon
47
Viridian Therapeutics
VRDN
$2.61B
– –
-614,010
Closed -$10.8M
1
2

Similar funds

OCM
Opti Capital Management New York $1.64B AUM 0% 1-Year Est. Return
LFS
Lutz Financial Services Omaha, Nebraska $1.64B AUM 15.04% 1-Year Est. Return
TIM
Triodos Investment Management Driebergen-Rijsenburg, Netherlands $1.64B AUM 37.98% 1-Year Est. Return
AAG
Armstrong Advisory Group Needham, Massachusetts $1.64B AUM 19.37% 1-Year Est. Return
MRG
Milestone Resources Group Road Town Tortola, British Virgin Islands $1.64B AUM 2.87% 1-Year Est. Return
EPW
Evolve Private Wealth Los Angeles, California $1.64B AUM
TWM
Tradition Wealth Management Edina, Minnesota $1.64B AUM 26.59% 1-Year Est. Return
MA
MONECO Advisors Fairfield, Connecticut $1.64B AUM 25.43% 1-Year Est. Return

MPM BioImpact's Q2 2024 Portfolio in Review

As of Q2 2024, MPM BioImpact held 47 positions worth $644M, up 3.5% from $622M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

MPM BioImpact deployed $87.7M of net new capital in Q2 2024, opening 9 new positions and adding to 25 existing holdings. Its largest new stake was Alkermes: 557,556 shares worth $13.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Sutro Biopharma, an estimated $4.16M trimmed.

  • MPM BioImpact's largest Q2 2024 buy was Alkermes: 557,556 shares worth $13.4M.
  • MPM BioImpact added most to ALX Oncology in Q2 2024, an estimated $11.2M increase.
  • MPM BioImpact's biggest Q2 2024 reduction was Sutro Biopharma, cutting an estimated $4.16M.
  • MPM BioImpact fully exited Geron in Q2 2024, selling an estimated $34.6M.
  • MPM BioImpact's ten largest holdings make up 54% of its $644M portfolio in Q2 2024.
  • MPM BioImpact opened 9 new positions and closed 3 in Q2 2024.
  • MPM BioImpact's portfolio value rose 3.5% quarter-over-quarter to $644M.

Based on MPM BioImpact's 13F filing for Q2 2024, filed 14 Aug 2024.